

**Amendments to the Specification:**

Please replace the paragraph beginning at page 13, line 10, with the following rewritten paragraph:

--As indicated in the Background section, the CMV genome contains an open reading frame designated US28 that encodes a protein that acts as a functional receptor for certain human and viral chemokines. Upon infection of a cell by CMV, US28 is expressed on the surface of the infected cell and becomes capable of responding to chemokines in the environment. Certain of the inventors have also shown that US28 is expressed on virions (see, e.g., published PCT application WO 02/18954 PCT Application No. 01/23792, filed on August 30, 2001, entitled "Inhibition of CMV Infection and Dissemination," and having attorney docket number 019934-002510PC). Since the CX3C chemokine, fractalkine, is expressed on certain endothelial cell surfaces and on populations of dendritic cells (DC) and binds with very high affinity to US28 ( $K_I$  = approximately 50 pM), the evidence indicates that it defines a portal through which CMV infected cells or virions go from the circulation to the tissue space, as well as finding residence in dendritic cells. Certain of the apparatus and methods which are provided take advantage of this aspect of CMV infection to collect CMV or CMV infected cells. In particular, the apparatus and methods use US28 chemomimetics (i.e., compounds that mimic US28 ligand activity) to retrieve CMV or CMV infected cells from an infected host. Such compounds can be utilized to induce migration of US28-bearing cells or virions *in vivo*; alternatively, the compounds capture such cells or virions as they come in contact with the compound. The compounds utilized can be of any of a number of types, such as proteins, peptides, peptide mimetics and the like. As described in greater detail below, a number of specific US28 small organic molecule mimetics have been identified that can be utilized in the methods and apparatus that are disclosed herein.--

Appl. No. 10/061,944  
Amdt. dated August 23, 2004  
Reply to Office Action of February 23, 2004

PATENT

Please replace the paragraph beginning at page 13, line 10, with the following rewritten paragraph:

-- Because CMV strains infect essentially all mammals, the apparatus and methods that are disclosed herein can be utilized to collect CMV and CMV infected cells from a variety of animals, including, for example, humans, non-human primates and a variety of commercial livestock. Further, the CMV to be removed can be wild-type CMV, or genetically engineered CMV. In some instances, the CMV is a genetically engineered virus useful for stimulating an immune response in a host, e.g., as described in PCT Application No. \_\_\_\_\_, No. PCT/US02/03229, filed February 1, 2002, entitled "~~Methods And Compositions Useful For Stimulating An Immune Response,~~" and having Attorney docket no. ~~019934-001610~~ and published as WO 02/062956, which is incorporated herein by reference for all purposes.--